Zydus joins once-weekly DPP-4 inhibitor fray
This article was originally published in Scrip
Executive Summary
Zydus Cadila has received US FDA approval to initiate Phase I trials for its candidate long-acting dipeptidyl peptidase IV (DPP-4) inhibitor for type 2 diabetes, joining a clutch of firms already in the development fray in the field including Merck & Co and Takeda.